Please login to the form below

Not currently logged in
Email:
Password:

Vectura to collaborate on COPD therapy

Respiratory disease specialist Vectura has said it is to collaborate with a 'leading pharmaceutical company' to develop and market new combination asthma/COPD therapy in the US

Respiratory disease specialist Vectura has said it is to collaborate with a 'leading pharmaceutical company' to develop and market a new combination asthma/COPD therapy in the US.

The unnamed company will replace Novartis' generics arm Sandoz in the deal to make use of Vectura's proprietary technology to bring investigational drug VR315 to the US market. Sandoz is continuing to develop for Europe.

Vectura will receive an initial payment of $10m, with $35m available in milestone payments. Royalties will also be available.

The company's partner will be responsible for the commercialisation and manufacture of the product together with clinical development.

Dr Chris Blackwell, CEO of Vectura, commented: "This is a major endorsement of the potential value of this product, Vectura's technology and product development expertise."

4th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics